Mapping and ablation of the functional substrate in ischemic heart disease with mini- micro- and conventional electrodes

Mapping and ablation of the functional substrate in ischemic heart disease with mini- micro- and conventional electrodes - Multielectrode functional substrate mapping

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50104

Enrollment

Registered

2021-01-27

Start date

2021-06-23

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart rhythm disorder Ventricular arrhythmia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Sustained within 6 months before enrolment. - Accepted for catheter ablation of VT. - Prior MI. The diagnosis of MI will be based on the presence of wall motion abnormalities, non-reversible perfusion defects and/or subendocardial or transmural late gadolinium enhancement areas in the perfusion territory of a significant stenotic coronary artery (>75 %).

Exclusion criteria

Exclusion criteria: - Age

Design outcomes

Primary

Measure	Time frame
Mapping accuracy of the micro-electrodes of the QDOT catheter in re- identifying evoked delayed potentials (EDP) detected by the Pentaray/Octrell catheter and confirmation of EDP elimination.	—

Secondary

Measure	Time frame
- Mapping time using the QDOT catheter to delineate EDP compared to functional substrate delineation with the Pentaray/Octrell catheter - Wave-front and pacing-rate (coupling interval) dependency of QDOT micro/conv. vs. Pentaray/Octrell for voltage mapping (=scar delineation) and functional substrate mapping (=EDP identification) - VT recurrence - All course mortality	—

Countries

Netherlands

Outcome results